Effect of probiotics as an immune modulator for the management of COVID-19

Ray, Mousumi; Manjunath, Ashwini; Halami, Prakash M.

doi:10.1007/s00203-023-03504-0

Cited by 10 publications

(3 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Probiotics mainly regulate the microbiota and immune system by regulating the innate system response and the production of anti‐inflammatory cytokines, thereby regulating the inflammatory and oxidative stress state of the body, and may regulate pneumonia and related symptoms. 159 , 160 A meta‐analysis found that probiotics shortened the length of hospital stay, recovery time, and reduced the risk of death, suggesting the potential of probiotics as an adjuvant therapy to reduce the risk of death and symptoms in COVID‐19. 161 Based on the gut–lung axis theory, there is a bidirectional interaction between gut microbiota and lung.…”

Section: Microbiota‐based Implications For Therapeutic Interventionsmentioning

confidence: 99%

Alterations in microbiota of patients with COVID‐19: implications for therapeutic interventions

Qiu,

Mo,

Chen

et al. 2024

MedComm

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) recently caused a global pandemic, resulting in more than 702 million people being infected and over 6.9 million deaths. Patients with coronavirus disease (COVID‐19) may suffer from diarrhea, sleep disorders, depression, and even cognitive impairment, which is associated with long COVID during recovery. However, there remains no consensus on effective treatment methods. Studies have found that patients with COVID‐19 have alterations in microbiota and their metabolites, particularly in the gut, which may be involved in the regulation of immune responses. Consumption of probiotics may alleviate the discomfort caused by inflammation and oxidative stress. However, the pathophysiological process underlying the alleviation of COVID‐19‐related symptoms and complications by targeting the microbiota remains unclear. In the current study, we summarize the latest research and evidence on the COVID‐19 pandemic, together with symptoms of SARS‐CoV‐2 and vaccine use, with a focus on the relationship between microbiota alterations and COVID‐19‐related symptoms and vaccine use. This work provides evidence that probiotic‐based interventions may improve COVID‐19 symptoms by regulating gut microbiota and systemic immunity. Probiotics may also be used as adjuvants to improve vaccine efficacy.

show abstract

Section: Microbiota‐based Implications For Therapeutic Interventionsmentioning

confidence: 99%

Alterations in microbiota of patients with COVID‐19: implications for therapeutic interventions

Qiu,

Mo,

Chen

et al. 2024

MedComm

View full text Add to dashboard Cite

show abstract

“…This memory response serves as a key step in understanding COVID-19 immunity and vaccine development ( Figure 2 ). Owing to suboptimal immune function, certain populations such as the elderly, those with underlying health issues, and immune compromised individuals, are highly susceptible to the severity of COVID-19 disease symptoms ( Ray et al., 2023 ). Furthermore, individual variability in immune responses may also lead to variances in disease severity and outcomes.…”

Section: Manifestation Of Innate and Adaptive Immune Cells During Sar...mentioning

confidence: 99%

COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens

Raj,

Bruce,

Anbalagan

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

The novel coronavirus disease 2019 (COVID-19) pandemic outbreak caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has garnered unprecedented global attention. It caused over 2.47 million deaths through various syndromes such as acute respiratory distress, hypercoagulability, and multiple organ failure. The viral invasion proceeds through the ACE2 receptor, expressed in multiple cell types, and in some patients caused serious damage to tissues, organs, immune cells, and the microbes that colonize the gastrointestinal tract (GIT). Some patients who survived the SARS-CoV-2 infection have developed months of persistent long-COVID-19 symptoms or post-acute sequelae of COVID-19 (PASC). Diagnosis of these patients has revealed multiple biological effects, none of which are mutually exclusive. However, the severity of COVID-19 also depends on numerous comorbidities such as obesity, age, diabetes, and hypertension and care must be taken with respect to other multiple morbidities, such as host immunity. Gut microbiota in relation to SARS-CoV-2 immunopathology is considered to evolve COVID-19 progression via mechanisms of biochemical metabolism, exacerbation of inflammation, intestinal mucosal secretion, cytokine storm, and immunity regulation. Therefore, modulation of gut microbiome equilibrium through food supplements and probiotics remains a hot topic of current research and debate. In this review, we discuss the biological complications of the physio-pathological effects of COVID-19 infection, GIT immune response, and therapeutic pharmacological strategies. We also summarize the therapeutic targets of probiotics, their limitations, and the efficacy of preclinical and clinical drugs to effectively inhibit the spread of SARS-CoV-2.

show abstract

“…The species most commonly used in probiotic and prebiotic clinical trials are Bifidobacterium longum and Bifidobacterium animalis subsp. Lactis, Bifidobacterium bifidum, Lacticaseibacillus rhamnosus, Lactobacillus acidophilus, Lactiplantibacillus plantarum, Limosilactobacillus reuteri, Loigolactobacillus coryniformis, Ligilactobacillus salivarius, Enterococcus faecium, and Saccharomyces cerevisiae (Figure 2) [115,119,120].…”

Section: Applications and Prospects Of Gut Microbiota For The Diagnos...mentioning

confidence: 99%

Dynamics of the Microbiota and Its Relationship with Post-COVID-19 Syndrome

Moreno-Corona,

López-Ortega,

Pérez-Martínez

et al. 2023

IJMS

View full text Add to dashboard Cite

Coronavirus disease (COVID-19) is an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can be asymptomatic or present with multiple organ dysfunction. Many infected individuals have chronic alterations associated with neuropsychiatric, endocrine, gastrointestinal, and musculoskeletal symptoms, even several months after disease onset, developing long-COVID or post-acute COVID-19 syndrome (PACS). Microbiota dysbiosis contributes to the onset and progression of many viral diseases, including COVID-19 and post-COVID-19 manifestations, which could serve as potential diagnostic and prognostic biomarkers. This review aimed to discuss the most recent findings on gut microbiota dysbiosis and its relationship with the sequelae of PACS. Elucidating these mechanisms could help develop personalized and non-invasive clinical strategies to identify individuals at a higher risk of experiencing severe disease progression or complications associated with PACS. Moreover, the review highlights the importance of targeting the gut microbiota composition to avoid dysbiosis and to develop possible prophylactic and therapeutic measures against COVID-19 and PACS in future studies.

show abstract

Effect of probiotics as an immune modulator for the management of COVID-19

Cited by 10 publications

References 140 publications

Alterations in microbiota of patients with COVID‐19: implications for therapeutic interventions

Alterations in microbiota of patients with COVID‐19: implications for therapeutic interventions

COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens

Dynamics of the Microbiota and Its Relationship with Post-COVID-19 Syndrome

Contact Info

Product

Resources

About